Studay Of Huayu Ruangan Capsule On Lipid Metabolism Of Non-Alcoholic Fatty Live Disease

Objective:To observing Huayu Ruangan Capsule on four non-alcoholic fatty liver disease(NAFLD)models of serum lipids(TC,TG,HDL-C,LDL-C),Effects of liver enzymes(AST,ALT)content,and on peroxisome proliferation-activated receptor alpha(PPARα),sterol regulatory element binding protein 1(Sterol-regulatory element binding proteins1,SREBP1)The influence of expression,to explore the mechanism of Huayu Ruangan Capsule in the treatment of qi stagnation and blood stasis type nonalcoholic fatty liver disease,and to provide experimental basis for the clinical use of Huayu Ruangan Capsule Methods:Sixty male SD rats were randomly divided into a blank group(12 rats)and a model group(48 rats)after one week of adaptive feeding.The blank group was fed normally,and the model was reproduced by the compound factor method of tail-tailing stimulation,high-fat diet induction and drug injection.After 8 weeks of modeling,3rats were randomly selected from the model group and the blank group to observe their general Condition,draw femoral artery blood to detect four blood lipids and liver function,HE staining to observe the pathological changes of liver tissue to verify the success of modeling.After successful modeling,45 NAFLD rats were randomly divided into 5 groups(9 in each group)according to the random number table method,in this order: negative control group,positive control group(rosuvastatin calcium tablet group),Chinese medicine high,Medium and low dose group(Huayu Ruangan Capsule high,medium and low dose group).After the model building,Huayu Ruangan Capsules were intragastrically administered with 1ml/100 g suspension of 0.24g/ml,0.16g/ml,0.08g/ml in the high,medium and low dose groups;Rosuvastatin calcium tablets The suspension of 0.5mg/ml was given by intragastric administration at 1ml/100 g.The normal group and the negative control group were given intragastric administration at 1ml/100 g physiological saline.The six groups were given intragastrically for 4 weeks,twice a day.After 4 weeks of intervention,the material is collected and tested.During the experiment,observe and record the general condition and weight of each group of rats;detect the four items of serum lipid and liver function;observe the pathological changes of liver tissue under lightmicroscope;detect the content of serum PPARα by ELISA;RT-PCR technology PPARα mRNA and SREBP1 mRNA levels in liver tissue;immunohistochemical method to detect the protein content of PPARα and SREBP1 in liver tissue.Results:1.Compared with the blank group,the negative control group had a larger body,irritability,decreased appetite,poor spirit,reduced activity,decreased sensitivity to reaction,yellow hair and messy hair,dark red eyes,dark tongue with ecchymosis The color of the mucous membranes on the skin and auricles is dull,and the stools are sticky and mostly unshaped.Compared with the negative control group,the general condition of rats in each drug intervention group has improved to varying degrees.2.The body weight of the rats showed an upward trend at the 4th,8th,and 12 th weeks,and the weight increase of the blank group was relatively stable.Compared with the blank group,he weight of the negative control group was obvious at the 4th,8th,and 12 th weeks.Increase,the body weight increase trend of the treatment group from 8 to 12 weeks is slower than that of the negative control group.3.Compared with the blank group,the serum levels of ALT,AST,TC,TG and LDL-C in the negative control group were significantly increased,and the serum HDL-C content was significantly reduced.Compared with the negative control group,the serum ALT,AST,TC,TG,LDL-C of rats in each treatment group were decreased to different degrees,and HDL-C was increased to different degrees.4.Observe the liver tissues of rats in each group under the light microscope.Compared with the blank group,there is obvious steatosis.Compared with the negative control group,the liver cell fatty lesions in each treatment group have different degrees of reduction.5.Compared with the blank group,the serum PPARα levels of rats in each group were reduced to different degrees;compared with the negative control group,the serum PPARα levels of the rats in each treatment group were increased to varying degrees except for the low-dose group of traditional Chinese medicine.6.Compared with the blank group,the positive expression of PPARα in the liver tissue of the negative control group was reduced.Compared with the negative control group,the positive expression of PPARα in the liver tissue of the drug intervention group increased;compared with the blank group,the positive control group SREBP1 was positive Compared with the negative control group,the expression of SREBP1 in the liver tissue of the drug intervention group was decreased compared with the negative control group.7.Compared with the blank group,the level of PPARα mRNA in the liver tissue of each group of rats decreased,and the level of PPARα mRNA of the negative control group decreased significantly;compared with the negative control group,the level of PPARα mRNA of each treatment group except the low-dose group of Chinese medicine showed different degrees Elevated;compared with the blank group,SREBP1 mRNA levels in the liver tissues of the negative control group the positive control group,and the low-dose group of Chinese medicine were increased;compared with the negative control group,the SREBP1 mRNA level in each treatment group was significantly reduced.Conclusion:1.There are obvious lipids in rats with qi stagnation and blood stasis NAFLD Abnormal mass metabolism.2.Huayu Ruangan Capsule can significantly reduce the serum ALT,AST,TC,TG,LDL-C content and increase the serum HDL-C content in NAFLD rats,indicating that Huayu Ruangan Capsule can effectively reduce blood lipids,improve liver function and promote Body lipid metabolism.3.High and middle doses of Huayu Ruangan Capsule can increase serum PPARαprotein content,PPARα mRNA level and protein expression in liver tissue;can reduce SREBP1 mRNA level and protein expression in liver tissue,and Huayu Ruangan Capsule treats Qi stagnation and blood stasis The mechanism of type NAFLD may be related to regulating the expression of PPARα and SREBP1,and then promoting the body’s lipid metabolism.PPARα and SREBP1 may be important targets of Huayu Ruangan capsule in the treatment of NAFLD.